Age-standardized pancreatic cancer mortality rates have not improved since 2010-2014.
-
-
The approval is based on an open-label, phase 2 trial.
-
An appeals period will run until February 26, with the final guidance to be published next month
-
Management of SCC is guided by the risk for metastasis.
-
Many believe social media increases patient awareness, education, and access.
-
Genetic changes are similar to those associated with skin melanoma.
-
Australian cost-effectiveness study shows primary prevention is low cost and effective.
-
Nivolumab monotherapy least expensive compared to other regimens.
-
French study suggests a partly common genetic etiology with keratinocyte carcinoma.
-
Mortality changes were most prevalent for cancer types with more approvals.
-
The draft decision is open for public comment until November 25, 2020
-
Patients in the real world differ from those included in clinical trials.
-
Nivolumab fails to secure NICE approval for adjuvant treatment of resected melanoma with lymph node involvement or metastatic disease.
-
Tazemetostat received accelerated FDA approval based on these findings.